Retinal tissue may degenerate for a number of reasons. Among them are: artery or vein occlusion, diabetic retinopathy, R.L.F./R.O.P. or disease (usually hereditary). Retinitis pigmentosa, retinoschisis, lattic degeneration, and macular degeneration are characterized by progressive types of retinal degeneration.
Researchers have found that the complement system seems to protect against retinal degeneration in retinitis pigmentosa.
The scientific research team from the Universidad Pablo de Olavide led by doctor José Antonio Sánchez Alcázar has published a new study in the international magazines Molecular Neorubiology and Neural Regeneration Research.
Eye research charity, Fight for Sight, is funding the development of an ‘organ-on-chip’ that for the first time will be used to help investigate glaucoma, a leading cause of blindness.
It was surprisingly simple. University of California, Berkeley, scientists inserted a gene for a green-light receptor into the eyes of blind mice and, a month later, they were navigating around obstacles as easily as mice with no vision problems.
Millions of Americans are progressively losing their sight as cells in their eyes deteriorate, but a new therapy developed by researchers at the University of California, Berkeley, could help prolong useful vision and delay total blindness.
How is a healthy retina cell like a tumor cell? It hijacks an energy-producing chemical reaction to churn out molecular building blocks. When tumor cells do it, they use the building blocks to make cancer grow and spread. But when retina cells do it, they renew photoreceptor membranes that keep our vision sharp.
Retinal dystrophies such as Age-related macular degeneration (AMD) are a major cause of vision loss in aging populations. National Eye Institute (NEI) estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020.
A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration.
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration.
A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness.
Sheets of fetal cells integrate into the retina and generate nearly normal visual activity in the brains of blind rats, reports new research published in JNeurosci.
Glaucoma, a disease that afflicts nearly 70 million people worldwide, is something of a mystery despite its prevalence. Little is known about the origins of the disease, which damages the retina and optic nerve and can lead to blindness.
Retinitis pigmentosa is a rare and hereditary neurodegenerative disease which causes vision loss due to the death of photoreceptors in the retina, and for which there is currently no treatment.
OHSU scientists have discovered a naturally occurring disease in monkeys that mimics a deadly childhood neurodegenerative disorder in people - a finding that holds promise for developing new gene therapies to treat Batten disease.
A new therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB. Neurodegeneration in this condition results from the abnormal accumulation of essential cellular molecules called mucopolysaccharides.
Researchers affiliated with the Kawasaki INnovation Gateway at SKYFRONT have developed new mouse models of retinal degeneration that enable transplantation of retinal sheets derived from human embryonic stem cells.
Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa.
Houston Methodist researchers developed a new lab-on-a-chip technology that could quickly screen possible drugs to repair damaged neuron and retinal connections, like what is seen in people with macular degeneration or who've had too much exposure to the glare of electronic screens.
More than 2 million people worldwide live with inherited and untreatable retinal conditions, including retinitis pigmentosa, which slowly erodes vision.
Duke Researchers have pinpointed a new therapeutic target for macular degeneration, an eye disease that affects over 10 million Americans and is the leading cause of blindness in adults over 60.